Page 274

41. Karpus WJ, Lukacs NW, McRae BL, Strieter RM, Kunkel SL, Miller SD. 1995. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol.; 155: 5003-10.

42. Kennedy KJ, Karpus WJ. 1999. Role of chemokines in the regulation of Th1/Th2 and autoimmune encephalomyelitis. J Clin Immunol.; 19: 273-9.

43. Koh DR, Fung-Leung WP, Ho A, Gray D, Acha-Orbea H, Mak TW. 1992. Less mortality butmore relapses in experimental allergic encephalomyelitis in CD8-/- mice. Science.; 256: 1210-3.

44. Kossut M, Juliano SL. 1999. Anatomical correlates of representational map reorganization induced by partial vibrissectomy in the barrel cortex of adult mice. Neuroscience.; 92: 807-17.

45. Kramer R, Zhang Y, Gehrmann J, Gold R, Thoenen H, Wekerle H. 1995. Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. Nat Med.; 1: 1162-6.

46. Krogsgaard M, Wucherpfennig KW, Canella B, et al. 2000. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J Exp Med. ; 191: 1395-412.

47. Li S, Stys PK. 2000. Mechanisms of ionotropic glutamate receptor-mediated excitotoxicity in isolated spinal cord white matter. J Neurosci.; 20: 1190-8.

48. Linington C, Bradl M, Lassmann H, Brunner C, Vass K. 1988. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol.; 130: 443-54.

49. Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ. 1999. High density synthetic oligonucleotide arrays. Nat Genet.; 21: 20-4.

50. Litzenburger T, Fassler R, Bauer J, et al. 1998. B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice. J Exp Med.; 188: 169-80.

51. Lodge PA, Johnson C, Sriram S. 1996. Frequency of MBP and MBP peptide-reactive T cells in the HPRT mutant T-cell population of MS patients. Neurology.; 46: 1410-5.

52. Louie AY, Huber MM, Ahrens ET, et al. 2000. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol.; 18: 321-5.

53. Lukes A, Mun-Bryce S, Lukes M, Rosenberg GA. 1999. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol.; 19: 267-84.

54. Luo L, Salunga RC, Guo H, et al. 1999. Gene expression profiles of laser-captured adjacent neuronal subtypes. Nat Med.; 5: 117-22.

55. Madsen LS, Andersson EC, Jansson L, et al. 1999. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet.; 23: 343-7.

56. Malenka RC, Nicoll RA. 1999. Long-term potentiation—a decade of progress? Science.; 285: 1870-4.

57. Malipiero U, Heuss C, Schlapbach R, Tschopp J, Gerber U, Fontana A. 1999. Involvement of the N-methyl-D-aspartate receptor in neuronal cell death induced by cytotoxic T cell-derived secretory granules. Eur J Immunol.; 29: 3053-62.

58. Martin R, Jaraquemada D, Flerlage M, et al. 1990. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol.; 145: 540-8.

59. Mathisen PM, Yu M, Johnson JM, Drazba JA, Tuohy VK. 1997. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J Exp Med.; 186: 159-64.

60. McDonald WI, Miller DH, Barnes D. 1992. The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol.; 18: 319-34.

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement